A multivalent vaccine and single platform diagnostic for bacterial respiratory diseases of pigs

Lead Research Organisation: London Sch of Hygiene and Trop Medicine
Department Name: Infectious and Tropical Diseases

Abstract

See main proposal

Technical Summary

See main proposal
 
Description Through this research program we were able to 1) improve the diagnosis, 2) understand the epidemiology and 3) produce improved vaccine candidates against three major pig pathognes Actinobacillus pleuropneumoniae, Streptpcoccos suis and Haemophilus parasuis
Exploitation Route Improved diagositcs, antimicrobials and vaccines
Sectors Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology

 
Description Bovine Tuberculosis
Amount £11,051,222 (GBP)
Funding ID BB/N004590/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2015 
End 09/2019
 
Description DSTL Glycoconjugate vaccine design
Amount £450,000 (GBP)
Organisation Defence Science & Technology Laboratory (DSTL) 
Sector Public
Country United Kingdom
Start 08/2011 
End 09/2014
 
Description DSTL Glycoconjugate vaccine design for Coxiella
Amount £600,000 (GBP)
Organisation Defence Science & Technology Laboratory (DSTL) 
Sector Public
Country United Kingdom
Start 07/2012 
End 08/2015
 
Description Developing and expanding the bacterial glycotoolbox for animal pathogens
Amount £200,000 (GBP)
Funding ID BB/M01925X/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2015 
End 09/2017
 
Description Development and application of an Advanced Glycan Production Platform
Amount £447,107 (GBP)
Funding ID BB/W006146/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 02/2022 
End 01/2025
 
Description Development and testing of a Streptococcus suis glycoconjugate vaccine
Amount £550,000 (GBP)
Organisation Research Councils UK (RCUK) 
Sector Public
Country United Kingdom
Start 03/2019 
End 03/2021
 
Description Development, production and testing of novel glycoconjugate pig vaccines
Amount £600,000 (GBP)
Funding ID BB/S004963/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 02/2019 
End 02/2021
 
Description Glycoengineering of Veterinary Vaccines
Amount £5,300,000 (GBP)
Funding ID BB/N001591/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 03/2016 
End 04/2021
 
Description Hilleman Labs 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Merck MSD 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution Collaboration on vaccine development
Collaborator Contribution Intellectual contribution and vaccine development and production
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Vabiotech vaccine production 
Organisation VabioTech
Country Viet Nam 
Sector Public 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production.
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Vaccine development for defence purposes 
Organisation Defence Science & Technology Laboratory (DSTL)
Country United Kingdom 
Sector Public 
PI Contribution New vaccine technology platform for making glycoconjugate vaccines against Burkholderia pseudomallei and Francisella tulerensis
Collaborator Contribution Technology know how, specific animal testing facilities
Impact Several vaccine candidates tested and some may go forward to vaccine trials
 
Title Attenuated Streptococcus suis bacterial cells 
Description Novel low cost Streptococcal suis vaccine 
IP Reference GB1704101.2 
Protection Patent granted
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact Improved pig vaccine
 
Company Name ArcVax 
Description A spin out company from LSHTM was set up in Dec 2016 to using Protein Glycan Coupling Technology to produce low cost glycoconjugate vaccines. Currently investment is being sought. 
Year Established 2016 
Impact To rapidly develop low cost candidate glycoconjugate vaccines, eg multiprotective vaccines for poultry.
 
Description TV Broadcasts 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact BBC Breakfast TV interview on vaccine design and antimicrobial resistance
BBC one interview on Campylobacter in Food chain
One Show BBC on antimicrobial resistance
Year(s) Of Engagement Activity 2015